XBiotech (XBIT) Price to Sales (2020 - 2022)

XBiotech has reported Price to Sales for 3 years, with the latest figure at 65.59 in Q3 2022.

• On a quarterly basis, Price to Sales fell 24.71% year-over-year to 65.59 in Q3 2022; TTM through Sep 2023 was 74.64, a 456.15% increase from a year earlier, with the FY2022 full-year figure at 26.64, up 44.66% from the prior year.
• Price to Sales was 65.59 for Q3 2022 at XBiotech, down from 112.01 in the prior quarter.
• The five-year high for Price to Sales was 525.99 in Q1 2022, with the low at 25.56 in Q2 2020.
• Average Price to Sales over 3 years is 116.16, with a median of 87.04 recorded in 2020.
• The largest YoY upside for Price to Sales was 395.54% in 2022 against a maximum downside of 24.71% in 2022.
• Over 3 years, Price to Sales stood at 87.04 in 2020, then declined by 13.5% to 75.29 in 2021, then declined by 12.88% to 65.59 in 2022.
• The last three Price to Sales figures came in at 65.59 (Q3 2022), 112.01 (Q2 2022), and 525.99 (Q1 2022), per Business Quant data.